Overview

Study of Irinotecan Liposome Injection in Patients With Advanced Biliary Tract Cancer

Status:
Not yet recruiting
Trial end date:
2024-08-01
Target enrollment:
Participant gender:
Summary
This study is an open-label, phase II study of irinotecan liposome injection in patients with advanced biliary tract cancer. The purpose of this study is to evaluate the safety, efficacy and pharmacokinetics of irinotecan liposome injection in patients with advanced biliary tract cancer.
Phase:
Phase 2
Details
Lead Sponsor:
CSPC Ouyi Pharmaceutical Co., Ltd.
Treatments:
Fluorouracil
Irinotecan
Leucovorin